Complement C3a treatment accelerates recovery after stroke via modulation of astrocyte reactivity and cortical connectivity

Overview
Related items

Longitudinal MRI including T2-weighted (T2w) and Diffusion Tensor Imaging (DTI) of WT mice with cortical stroke lesions induced by photothrombosis (PT) monitored for 8 weeks (8 wks). The mice received either intranasal C3a (complement factor) or PBS treatment from day 7 to day 28 post stroke.

Programme: Aswendt Lab

SEEK ID: https://ldh.stroke-koeln.imise.uni-leipzig.de/projects/6

Public web page: Not specified

NFDI4Health PIs: No PIs for this Project

Project created: 4th Nov 2024

Extended Metadata (Nfdi4Health MDS 3.3)

Expand All Collapse All

Resource classification(*)

Type of the resource(*) : Study

Title(s)/name(s) of the Project

Title/name(*) : Complement C3a treatment accelerates recovery after stroke via modulation of astrocyte reactivity and cortical connectivity
Language of the title/name(*) : English

Acronym(s) of the Project

Acronym(*) : Not specified
Language of the acronym(*) : Not specified

Description(s) of the Project

Description(*) : Longitudinal MRI including T2-weighted (T2w) and Diffusion Tensor Imaging (DTI) of WT mice with cortical stroke lesions induced by photothrombosis (PT) monitored for 8 weeks (8 wks). The mice received either intranasal C3a (complement factor) or PBS treatment from day 7 to day 28 post stroke.
Language of the description(*) : Not specified

Keyword(s) describing the Project

Keyword(*) : stroke, functional recovery, neuroinflammation, neuroimaging, complement system

Language(s) of the project : English

Contributor(s) of the Project

Is it a personal or organisational contribution?(*) : Personal
Details about the contributing organisation(s)/institution(s)/group(s)
Contributor type(*) : Creator/Author
Funding identifier(s) : Project-ID 431549029 – SFB 1451
Name of the organisation/institution/group(*) : University of Cologne
Details about the contributing person(s)
Contributor type(*) : Principal investigator
Given name(*) : Markus
Family name(s)(*) : Aswendt
Digital identifier(s)
Identifier(*) : 0000-0003-1423-0934
Scheme(*) : ORCID
Email address : Not specified
Phone number : Not specified
Organisation(s) associated with the contributor
Name(*) : Not specified
Address : Not specified
Web page : Not specified
Digital identifier(s)
Identifier(*) : Not specified
Scheme(*) : Not specified

Alternative identifiers

Type of the registry(*) : Not specified
Identifier(*) : Not specified

Characteristics of the Project

Is it an interventional or non-interventional Project? : Non-interventional
Specification of the type of the Project
Interventional Project type : []
Non-interventional Project type : []
Primary health condition(s) or disease(s) considered in the Project
Primary health condition or disease name(*) : Not specified
Terminology/classification(*) : Not specified
Code of the health condition or disease : Not specified
Groups of diseases or conditions(*)
Which groups of diseases or conditions were the data collected on? : Diseases of the nervous system (VI)
On which diseases or conditions were the data collected? : Lower level ICD-10 (https://icd.who.int/browse10/2019/en), with autocomplete
Collects mortality data? : Not specified
Administrative information about the Project
Status of the ethics committee approval : Not specified
Overall Project status : Not specified
Participants enrolled by invitation? : Not specified
Start date : Not specified
End date : Not specified
Mono- or multicentric? : Not specified
Number of centers : Not specified
One or more data providers? : Not specified
Number of data providers : Not specified
Primary subject(*) : Animal
Eligibility criteria for Project participants
Eligibility criteria: Minimum age
Minimum eligible age(*) : Not specified
Unit of age(*) : Not specified
Eligibility criteria: Maximum age
Maximum eligible age(*) : Not specified
Unit of age(*) : Not specified
Eligible gender : []
Inclusion criteria : Not specified
Exclusion criteria : Not specified
Population of the Project(*)
Coverage : Not specified
Country(ies) : []
Region(s) and/or city(ies) : Not specified
Interventions of the Project
Name of the intervention(*) : Not specified
Type of the intervention : Not specified
Additional information about the intervention : Not specified
Name(s) of the arm(s) associated with the given intervention : Not specified
Exposures of the Project
Name of the exposure : Not specified
Type of the exposure : Not specified
Additional information about the exposure : Not specified
Name(s) of the group(s) associated with the given exposure : Not specified
Outcome measures in the Project
Name of the outcome measure(*) : Not specified
Description of the outcome measure : Not specified
Type of the outcome measure : Not specified
Time point(s) of assessment : Not specified
Additional information about the Project : Not specified
Additional assessments/measurements in the Project : []
Data sharing strategy of the Project(*)
Is it planned to share the data?(*) : Not specified
Supporting documents available in addition to the data : []
When and for how long will the data be available? : Not specified
Criteria for data access : Not specified
Additional information about data sharing : Not specified
DataSHIELD/Opal infrastructure available? : Not specified
Link to data request application : Not specified
Web page with additional information about data sharing : Not specified
Record linkage possible? : Not specified
Non-interventional aspects of the Project
Temporal design : []
Target follow-up duration of the Project
Target follow-up duration(*) : Not specified
Unit of time(*) : Not specified
Number of follow-ups conducted : Not specified
Biosamples retained in a biorepository : []
Specific types of retained biosamples : Not specified
Interventional aspects of the Project
Numerical phase : Not specified
Masking of intervention(s) assignment
Masking implemented? : Not specified
Who is masked? : []
Additional information about masking : Not specified
Type of allocation of participants to an arm : Not specified
Off-label use of a drug product : Not specified

Complement C3a treatment accelerates recovery after stroke via modulation of astrocyte reactivity and cortical connectivity

Files:

inputs

Complement C3a treatment accelerates recovery after stroke via modulation of astrocyte reactivity and cortical connectivity

Related items

Files:

inputs